Subscribe to RSS
DOI: 10.1055/s-2005-858274
© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York
Adalimumab bei Patienten mit therapierefraktärem M. Crohn - die nächste Generation der anti-TNF-α-Therapie?
Adalimumab in Infliximab Refractory Crohn's Disease - the next Generation of anti-TNF-α-therapy?Publication History
Publication Date:
07 July 2005 (online)
Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, Paavola J, Lee SK, Price J, Targan SR, Abreu MT. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100: 75 - 79
Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK, Gaiennie J, Smith K, Do J, Abreu MT. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10: 333 - 338
Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 2004; 99: 1984 - 1989
Prof. Dr. med. T. Kucharzik
Medizinische Klinik und Poliklinik B, Universitätsklinikum Münster
Albert-Schweitzer-Str. 33
D-48129 Münster
Phone: 02 51/8 34 75 74
Fax: 02 51/8 34 75 76
Email: kucharz@uni-muenster.de